Eptinezumab trial for kids with episodic migraine
Treatments studied
Part of Brain & nervous system, Pain clinical trials.
This Phase 3 study tests eptinezumab to reduce migraine attacks in children who have episodic migraine (not daily chronic migraine). It may help by lowering the number of headache days and migraine days over time. You must complete a headache diary during screening to be considered.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child has migraine diagnosed by a headache specialist, with headache history for at least 6 months
- During the 28-day screening period, you must fill in the headache eDiary at least 23 days out of 28
- During the 28-day screening period, headaches must be 14 days or fewer, including at least 4 migraine days
- Your migraines should not be unusual types (for example: migraine with brainstem aura or other atypical migraine symptoms)
- You must not have other headache types like chronic daily tension-type, cluster, or similar diagnoses
- Any major brain/neurologic injury or uncontrolled psychiatric condition that needs urgent treatment may rule you out
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
This trial tests eptinezumab, a preventive medicine, to reduce headache frequency in teens with chronic migraine. It may help your teen if they have frequent migraine days despite usual care.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
This real-world study looks at how well eptinezumab (an antibody medicine for migraine prevention) works for people with frequent episodic or chronic migraine as they get usual care. You may be asked to share health information and treatment details to see what helps most in everyday life.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
Hear when a new Episodic Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.